Literature DB >> 23293749

TRA-1-60+, SSEA-4+, Oct4A+, Nanog+ Clones of Pluripotent Stem Cells in the Embryonal Carcinomas of the Ovaries.

Marek Malecki1, Mark Anderson2, Michael Beauchaine3, Songwon Seo4, Xenia Tombokan5, Raf Malecki6.   

Abstract

INTRODUCTION: Embryonal carcinoma of the ovary (ECO), pure or admixed to other tumors, is the deadly gynecological cancer. SPECIFIC AIM: The specific aim of this work was identification, isolation, clonal expansion, and molecular profiling of the pluripotent cells in the embryonal carcinomas of the ovaries. PATIENTS
METHODS: The samples were acquired from the patients, who were clinically and histopathologically diagnosed with the advanced, pure embryonal carcinomas of the ovaries. The cell surface display of the TRA-1-60 and SSEA-4 was analyzed by flow cytometry (FCM), immunoblotting (IB), multiphoton fluorescence spectroscopy (MPFS), nuclear magnetic resonance spectroscopy (NMRS), and total reflection x-ray spectroscopy (TRXFS). The transcripts of the Oct4A and Nanog were analyzed by qRTPCR and MPFS and the products by MPFS. The human pluripotent, embryonic stem cells (ESC), human pluripotent, embryonal carcinoma of the testes (ECT), healthy tissues of the ovary (HTO), healthy tissue of testes (HTT), peripheral blood mononuclear cells (PBMC), and bone marrow mononuclear cells (BMMC) served as the controls.
RESULTS: The studied embryonal carcinomas of the ovaries (ECOs) contained the cells with the strong surface display of the TRA-1-60 and SSEA-4, which was similar to the pluripotent ESC and ECT. Their morphology was consistent with the histopathological diagnosis. Moreover, these cells showed strong expression of the Oct4A and Nanog, which was similar to the pluripotent ESC and ECT. The ECO cells formed embryoid bodies, which differentiated into ectoderm, mesoderm, and endoderm. These cells were induced to differentiate into muscles, epithelia, and neurons.
CONCLUSION: Herein, we revealed presence and identified molecular profiles of the clones of the pluripotent stem cells in the embryonal carcinomas of the ovaries. These results should help us with refining molecular diagnoses of these deadly neoplasms and design biomarker-targeted, patient-centered, personalized therapy.

Entities:  

Keywords:  Cancer of the ovary; embryonal carcinoma of the ovary; germ cell tumor; pluripotent stem cell; stage specific embryonic antigen 4 (SSEA-4); tumor resistance antigen 1-60 (TRA-1-60); variable fragment antibody

Year:  2012        PMID: 23293749      PMCID: PMC3535320     

Source DB:  PubMed          Journal:  J Stem Cell Res Ther


  65 in total

1.  FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics.

Authors:  S Pecorelli; J L Benedet; W T Creasman; J H Shepherd
Journal:  Int J Gynaecol Obstet       Date:  1999-06       Impact factor: 3.561

2.  TRA-1-60: a new serum marker in patients with germ-cell tumors.

Authors:  J Marrink; P W Andrews; P J van Brummen; H J de Jong; D T Sleijfer; H Schraffordt Koops; J W Oosterhuis
Journal:  Int J Cancer       Date:  1991-09-30       Impact factor: 7.396

3.  Retinoic acid directs neuronal differentiation of human pluripotent stem cell lines in a non-cell-autonomous manner.

Authors:  Peter D Tonge; Peter W Andrews
Journal:  Differentiation       Date:  2010-04-28       Impact factor: 3.880

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 5.  Circulating tumor cells as emerging tumor biomarkers in breast cancer.

Authors:  Evi S Lianidou; Athina Markou
Journal:  Clin Chem Lab Med       Date:  2011-07-29       Impact factor: 3.694

6.  Isolation of single, intact chromosomes from single, selected ovarian cancer cells for in situ hybridization and sequencing.

Authors:  Marek Malecki; Waclaw Szybalski
Journal:  Gene       Date:  2011-12-01       Impact factor: 3.688

7.  Expression of CD30 and CD30 ligand in cultured cell lines from human germ-cell tumors.

Authors:  M F Pera; W Bennett; D P Cerretti
Journal:  Lab Invest       Date:  1997-04       Impact factor: 5.662

8.  Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer.

Authors:  A Blythe Ryerson; Christie Eheman; Joseph Burton; Nancy McCall; Don Blackman; Sujha Subramanian; Lisa C Richardson
Journal:  Obstet Gynecol       Date:  2007-05       Impact factor: 7.661

9.  Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling.

Authors:  Kristian Almstrup; Christina E Hoei-Hansen; Ute Wirkner; Jonathon Blake; Christian Schwager; Wilhelm Ansorge; John E Nielsen; Niels E Skakkebaek; Ewa Rajpert-De Meyts; Henrik Leffers
Journal:  Cancer Res       Date:  2004-07-15       Impact factor: 12.701

10.  Association of reactive oxygen species levels and radioresistance in cancer stem cells.

Authors:  Maximilian Diehn; Robert W Cho; Neethan A Lobo; Tomer Kalisky; Mary Jo Dorie; Angela N Kulp; Dalong Qian; Jessica S Lam; Laurie E Ailles; Manzhi Wong; Benzion Joshua; Michael J Kaplan; Irene Wapnir; Frederick M Dirbas; George Somlo; Carlos Garberoglio; Benjamin Paz; Jeannie Shen; Sean K Lau; Stephen R Quake; J Martin Brown; Irving L Weissman; Michael F Clarke
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

View more
  13 in total

1.  Improved targeting and enhanced retention of the human, autologous, fibroblast-derived, induced, pluripotent stem cells to the sarcomeres of the infarcted myocardium with the aid of the bioengineered, heterospecific, tetravalent antibodies.

Authors:  Marek Malecki
Journal:  J Stem Cell Res Ther       Date:  2013-05-06

Review 2.  Automated Chemical Oligosaccharide Synthesis: Novel Approach to Traditional Challenges.

Authors:  Matteo Panza; Salvatore G Pistorio; Keith J Stine; Alexei V Demchenko
Journal:  Chem Rev       Date:  2018-06-28       Impact factor: 60.622

3.  Detecting TRA-1-60 in Cancer via a Novel Zr-89 Labeled ImmunoPET Imaging Agent.

Authors:  Jordan M White; Akhila N Kuda-Wedagedara; Madison N Wicker; Daniel E Spratt; William M Schopperle; Elisabeth Heath; Nerissa T Viola
Journal:  Mol Pharm       Date:  2020-02-28       Impact factor: 4.939

4.  Suicide Gene Therapy for Cancer - Current Strategies.

Authors:  Paul Zarogoulidis; Kaid Darwiche; Antonios Sakkas; Lonny Yarmus; Haidong Huang; Qiang Li; Lutz Freitag; Konstantinos Zarogoulidis; Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2013-08-09

5.  Frontiers in Suicide Gene Therapy of Cancer.

Authors:  Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2012-10-22

6.  TRA-1-60+, SSEA-4+, POU5F1+, SOX2+, NANOG+ Clones of Pluripotent Stem Cells in the Embryonal Carcinomas of the Testes.

Authors:  Marek Malecki; Xenia Tombokan; Mark Anderson; Raf Malecki; Michael Beauchaine
Journal:  J Stem Cell Res Ther       Date:  2013-04-02

7.  Outer brain barriers in rat and human development.

Authors:  Christian B Brøchner; Camilla B Holst; Kjeld Møllgård
Journal:  Front Neurosci       Date:  2015-03-16       Impact factor: 4.677

8.  Safety and efficacy of suicide gene therapy with adenosine deaminase 5-fluorocytosine silmutaneously in in vitro cultures of melanoma and retinal cell lines.

Authors:  Antonios Sakkas; Paul Zarogoulidis; Kalliopi Domvri; Wolfgang Hohenforst-Schmidt; Dimitris Bougiouklis; Stylianos Kakolyris; Thomas Zarampoukas; Ioannis Kioumis; Georgia Pitsiou; Haidong Huang; Qiang Li; Soultana Meditskou; Theodora Tsiouda; Nikolaos Pezirkianidis; Konstantinos Zarogoulidis
Journal:  J Cancer       Date:  2014-04-17       Impact factor: 4.207

Review 9.  Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis.

Authors:  Sigrid Marie Kraggerud; Christina E Hoei-Hansen; Sharmini Alagaratnam; Rolf I Skotheim; Vera M Abeler; Ewa Rajpert-De Meyts; Ragnhild A Lothe
Journal:  Endocr Rev       Date:  2013-04-10       Impact factor: 19.871

10.  Eradication of Human Ovarian Cancer Cells by Transgenic Expression of Recombinant DNASE1, DNASE1L3, DNASE2, and DFFB Controlled by EGFR Promoter: Novel Strategy for Targeted Therapy of Cancer.

Authors:  Marek Malecki; Jessica Dahlke; Melissa Haig; Lynn Wohlwend; Raf Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2013-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.